JPRN-jRCT2080221812未知3 期
A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction
ovartis Pharma K.K.0 个研究点目标入组 28 人开始时间: 2012年5月25日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •*Renal findings: Hypertensive patients with renal dysfunction and stable renal condition at least 4 weeks before screening visit.
- •*Satisfy office msSBP>=140 mmHg and <180 mmHg at baseline.
排除标准
- •*Patients show msDBP >=110 mmHg and/or msSBP >=180 mmHg.
- •*History of angioedema, drug-related or otherwise, as reported by the patient.
- •*Any other following renal disorder:
- •*Patients on renal failure
- •*Patients on dialysis
- •*Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究者
相似试验
未知
3 期
Open Label Study of Treatment With LCZ696 in Patients With Severe HypertensioSevere HypertensionJPRN-jRCT2080221859ovartis Pharma K.K.34
已完成
不适用
[18F]THK-5351 PET Study of Normal, Mild Cognitive Impairment, Alzheimer’s Disease and Other Neurodegenerative DiseaseKCT0001785Asan Medical Center180
进行中（未招募）
1 期
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular DystrophyEUCTR2016-005023-92-Outside-EU/EEASarepta Therapeutics, Inc.40
进行中（未招募）
1 期
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular DystrophyEUCTR2016-005024-28-Outside-EU/EEASarepta Therapeutics, Inc.24
进行中（未招募）
不适用
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccineovartis Meningococcal ACWY conjugate vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis serogroups A, C, W and Y.EUCTR2014-004903-63-Outside-EU/EEAovartis Vaccines and Diagnostics Inc.825